ALMS Stock Price, Analysis & Fundamentals

Analysis

Alumis Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $867.51 million and a revenue of $22.12 million (TTM). The company has 221 employees. The financial health of Alumis Inc. is characterized by significant net losses, with a net income (TTM) of -$245,152,992 and EBITDA of -$439,332,000. This is reflected in the operating margin of -5372.3% and profit margin of 0.0%. The company's returns on equity and assets are also negative at -66.9% and -61.5%, respectively. Alumis Inc.'s balance sheet shows $377.72 million in cash and $37.80 million in debt, resulting in a debt to equity ratio of 9.82. The valuation context for Alumis Inc. is notable due to the negative P/E ratio (TTM) of -2.59 and forward P/E of -2.59. Additionally, the price to sales ratio is 39.22, which may be considered high in comparison to other companies.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Alumis Inc.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Visit website →

ALMS

Price History (1Y)

Analysis

About Alumis Inc.

Key Statistics

Company Info